Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.54 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365210 | 0.83 | TRPV1 (0.67) | TRPV1 | |
| SCHEMBL14083595 | 0.79 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL14083354 | 0.78 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL6364274 | 0.78 | TRPV1 (0.74) | TRPV1 | |
| SCHEMBL14083596 | 0.76 | ALDH1A1 (0.53) | TRPV1ALDH1A1LMNAGAAMAPT | |
| SCHEMBL4814175 | 0.75 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL14083351 | 0.74 | ALDH1A1 (0.53) | TRPV1ALDH1A1GAAMAPT | |
| SCHEMBL14083162 | 0.74 | TRPV1 (0.62) | TRPV1 | |
| SCHEMBL14083327 | 0.73 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL14083188 | 0.73 | MAPT (0.52) | ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165015-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | claimed |
| WO-2005073193-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050165015-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165015-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885HIF1A 1180/4885EPAS1 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.